You are here
Convenience, Compliance and Overcoming Clinical Inertia for Primary Care Physicians
In this course you will learn about basal insulin–glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy, and how the efficacy and safety of this approach surpasses that of the individual components. The course will provide information on how to identify patients who are most likely to benefit from this combination. Practical considerations will be discussed, including tips on how to best manage patients during treatment with basal insulin–GLP-1 receptor agonist combination therapy.
Basal Insulin–GLP-1 RA Combination Therapy: Convenience, Compliance, and Overcoming Clinical Inertia
In this webcast, Professor Khunti addresses the issue of clinical inertia, and discusses why patients often do not achieve glycaemic targets. He also discusses the rationale for earlier insulin initiation and how clinical inertia may be overcome.
In this roundtable discussion, Professor Wilding, Professor Cos, and Professor Harris discuss different oral and injectable therapies and their advantages and limitations. They also talk about the practical considerations when choosing the best therapy for a patient and the potential of new fixed-dose basal insulin–GLP-1 RA combination therapy.